Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management. Issue 43 (11th September 2018)

• Record Type: Journal Article
• Authors: Zhang, Can Yang; Gao, Jin; Wang, Zhenjia
• Is Part Of: Advanced materials. Volume 30:Issue 43(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-09-11
• Subjects: infectious microenvironments -- nanoparticle -- sepsis -- targeted drug delivery; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.201803618
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract: Sepsis is a life‐threatening disease resulted from a dysregulated host immune response to bacterial infections, continuing to cause high morbidity and mortality worldwide. Despite discoveries of many potential therapeutic targets, effective treatments of sepsis are lacking. Here, a strategy is reported to target infectious microenvironments (IMEs) via bioresponsive nanoparticles that simultaneously eliminate bacteria and alleviate the host inflammation response, thus managing sepsis in mice. The nanoparticle is made of copolymers sensitive to pH and bacterial enzymes to self‐assemble into a micelle loaded with both an antibiotic (ciprofloxacin) and an anti‐inflammatory agent ((2‐[(aminocarbonyl)amino]‐5‐(4‐fluorophenyl)‐3‐thiophenecarboxamide). In addition, the nanoparticle is conjugated with intercellular adhesion molecule‐1 antibodies to target IMEs. Nanoparticle targeting to IMEs and local cues as triggers to deliver therapeutics in on‐demand manners is demonstrated using an acute lung bacterial infection mouse model. In the sepsis mouse model induced by peritonitis at a lethal dose of bacterial invasion, it is shown that concurrently targeting pathogens and excessive inflammation pathways is valuable to manage the sepsis. The study illustrates not only the development of a new delivery system but also the mechanism‐based therapy of nanomedicine for infectious diseases. Abstract : Stimuli‐responsive nanoparticles loaded with antibiotic and anti‐inflammatory agents can specifically target infection sites via binding to intercellular adhesion molecule‐1 (ICAM‐1) expressed on inflamed endothelium. The nanoparticles are composed of pH/enzyme‐responsive copolymers and anti‐mouse ICAM‐1 antibody, and drug release is triggered by infectious microenvironments. The studies show concurrently eliminating pathogens and mitigating host inflammation responses are valuable to manage sepsis.